S??curisation de l???emploi des chimioth??rapies anticanc??reuses administrables par voie orale, Le Pharmacien Hospitalier, vol.44, issue.1, pp.36-44, 2009. ,
DOI : 10.1016/j.phhp.2008.12.002
ligue-cancer.net/article/le-cancer/qu-est-ce-que-le-cancer--septembre, 2009. ,
e-cancer.fr/les-soins/dispositif-d-annonce/outils-de-liaison-medecin? ide/doc_download/1285-la-situation-du-cancer-en, 2009. ,
Patient preferences for oral versus intravenous palliative chemotherapy., Journal of Clinical Oncology, vol.15, issue.1, pp.110-115, 1997. ,
DOI : 10.1200/JCO.1997.15.1.110
A randomized crossover trial comparing oral UFT (uracil/tegafur)+leucoverin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer, Proc Am Soc Clin Oncol, vol.19, 2000. ,
Patient noncompliance with self-administered chemotherapy, Cancer, vol.37, issue.1, pp.17-22, 1990. ,
DOI : 10.1002/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO;2-I
The Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer, The Oncologist, vol.6, issue.1, pp.56-64, 2001. ,
DOI : 10.1634/theoncologist.6-1-56
Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting, Oncology, vol.72, issue.3-4, pp.248-254, 2007. ,
DOI : 10.1159/000113016
Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents, Clinical Pharmacokinetics, vol.123, issue.1, pp.1127-56, 2004. ,
DOI : 10.2165/00003088-200443150-00005
Number and nature of drug interactions concerning antineoplasic drugs, Bull Cancer, vol.94, issue.5, pp.477-82, 2007. ,
Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction, Clinical Pharmacology & Therapeutics, vol.68, issue.4, pp.345-355, 2000. ,
DOI : 10.1067/mcp.2000.109797
Severe Pustular Eruption Associated with Imatinib and Voriconazole in a Patient with Chronic Myeloid Leukemia, Dermatology, vol.211, issue.4, pp.363-368, 2005. ,
DOI : 10.1159/000088510
Significant drug interaction: Phenytoin toxicity due to erlotinib, Lung Cancer, vol.57, issue.3, pp.404-410, 2007. ,
DOI : 10.1016/j.lungcan.2007.02.011
Médecines complémentaires et alternatives suivies par les patients cancéreux de France, Bull Cancer, vol.94, issue.5, pp.483-491, 2007. ,
Induction of imatinib metabolism by hypericum perforatum, Blood, vol.104, issue.4, pp.1229-1259, 2004. ,
DOI : 10.1182/blood-2004-04-1240
Role of Patient Compliance in Clinical Pharmacokinetics, Clinical Pharmacokinetics, vol.27, issue.3, pp.202-217, 1994. ,
DOI : 10.2165/00003088-199427030-00004
Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer, New England Journal of Medicine, vol.304, issue.1, pp.10-15, 1981. ,
DOI : 10.1056/NEJM198101013040103
Attributions of responsibility in adolescent cancer patients and their parents, Journal of Cancer Education, vol.4, issue.2, pp.135-177, 1989. ,
DOI : 10.1080/08858198909527987
Treatment compliance in childhood and adolescence. Cancer, pp.3441-3450, 1993. ,
Relationships Between Behavioral Factors and Diabetic Control in Children and Adolescents: A Camp Study, Psychosomatic Medicine, vol.44, issue.4, pp.321-360, 1982. ,
DOI : 10.1097/00006842-198209000-00002
Therapeutic patient education: continuing education programmes for healthcare providers in the field of prevention of chronic diseases, Copenhagen: WHO Europe, 1998. ,
L'éducation thérapeutique en cancérologie : vers une reconnaissance des compétences du patient, Bull Cancer, vol.94, issue.3, pp.267-74, 2007. ,
Cancer du sein : http://www.ligue-cancer.net/article/317_cancer-du-sein?gclid=CNLw0fmA7Z8CFR-Y2AodiDS0Xg - Février, 2010. ,
Prevention and management of oral mucositis in patients with cancer, seminars in oncology nursing, pp.201-212, 2007. ,
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis, Cancer, vol.95, issue.S9, pp.2026-2046, 2004. ,
DOI : 10.1002/cncr.20163
Mucosal diseases series, oral diseases, pp.229-241, 2006. ,
Diagnosis and management of oral mucositis, supportive oncology, pp.13-21, 2007. ,
Updated clinical practice guidelines for the prevention and treatment of mucositis, cancer, pp.820-83, 2007. ,
New strategies for management of oral mucositis in cancer patients, 2005, supportive oncology, pp.9-13, 2006. ,
Interventions for preventing oral mucositis for patients with cancer receiving treatment, cochrane database of systematic reviews, 2006. ,
Interventions for treating oral mucositis for patients with cancer receiving treatment, cochrane database of systematic reviews, 2007. ,
Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis, support care cancer, pp.528-532, 2006. ,
A comparison of patients' perceptions of oral cancer treatments and intravenous cancer treatments: what the health care team needs to know, Proceedings of the American Society of Clinical Oncology, vol.22, p.746, 2003. ,
Fully oral chemotherapy regimens, patient's or physician's preference, Proceedings of the American Society of Clinical Oncology, vol.22, p.777, 2003. ,